CS
ADPT icon

Candriam SCA’s Adaptive Biotechnologies ADPT Stock Holding History

Candriam SCA’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,058
Closed -$89.6K – 677
2025
Q1 		$89.6K Buy
+12,058
New +$92.7K ﹤0.01% 672
2023
Q1 		– Sell
-111,982
Closed -$856K – 876
2022
Q4 		$856K Buy
111,982
+1,489
+1% +$11.6K 0.01% 730
2022
Q3 		$787K Buy
+110,493
New +$1.04M 0.01% 762

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Candriam SCA's ADPT Position: Q2 2025 in Review

Candriam SCA sold out of Adaptive Biotechnologies (ADPT) in Q2 2025, closing a stake of 12,058 shares — an estimated $89.6K sold.

Candriam SCA first reported a position in ADPT in Q3 2022 and held it in 3 quarters. The position peaked at $856K in Q4 2022. 242 funds tracked by Wall St. Rank hold ADPT as of Q2 2025.

  • Candriam SCA reported no remaining Adaptive Biotechnologies position as of Q2 2025 after selling out during the quarter.
  • Candriam SCA sold 12,058 Adaptive Biotechnologies shares in Q2 2025, an estimated $89.6K.
  • Candriam SCA first reported a position in Adaptive Biotechnologies in Q3 2022 and held it in 3 quarters.
  • Candriam SCA's Adaptive Biotechnologies position peaked at $856K in Q4 2022.
  • 242 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2025.

Based on Candriam SCA's 13F filing for Q2 2025, filed 8 Aug 2025.